PHARM.D

FDA Approves Fidaxomicin for C difficile Treatment Emma Hitt, PhD The US Food and Drug Administration (FDA) on Friday approved the macrolide antibacterial fidaxomicin ( Dificid , Optimer Pharmaceuticals Inc) for the treatment of Clostridium difficile –associated diarrhea (CDAD). Approval of fidaxomicin tablets was based on 2 trials involving 564 patients with CDAD. In those trials, fidaxomicin was shown to have efficacy and safety similar to those of vancomycin. The trials also showed that more patients treated with fidaxomicin had a sustained response 3 weeks after treatment ended than patients treated with vancomycin. The most common adverse effects included nausea, vomiting, headache, abdominal pain, and diarrhea. In April this year, upon reviewing results of the 2 studies, the FDA's Anti-Infective Drugs Advisory Committee unanimously recommended fidaxomicin for the treatment of life-threatening C difficile–associated diarrhea. "In recent years, many in the infectiou

     Registration procedure for pharm.D students passed out Hi friends as per Pci rules and regulations we have added download link for "Registration procedure for pharm.D students passed out" click the link below and download the procedure document                                                                                                         yours                                                                                                pharmdsrmc NOTE: To view the document you need MS office 2003 or higher CLICK TO DOWNLOAD

Hai friends as per the PCI rules and regulations we have added the web link for "pharm.D syllabus india" Now you can download the  syllabus copy through the web link given below.                                                                             yours,                                                                        pharmdsrmc. CLICK TO DOWNLOAD     alternate direct download just click  http://www.pci.nic.in/  and then click on rules and regulations and then click on pharmdregulations and the syllabus will be downloaded.

                         Do's and don'ts to control hyperacidity Do's- Drink 1-2 glasses of water early morning to stay healthy and acidity- free Eat carbohydrate rich food like rice, which is easy to digest without any acid formation Eating bananas help prevent the symptoms of acidity and heartburn Vegetables like sweet potatoes, carrot and beet root are effective ion fighting acidity Exercise daily Don'ts- Don't eat fried and oily food Avoid intake of coffee, tea and soft drinks Avoid eating citrus fruits, such as sweet lime and oranges, as they have high acid content Don't smoke, or consume alcohol Avoid late nights, as inadequate sleep can lead to severe acidity Avoid going to bed immediately after having dinner In Acidity, do not take self-medication or over the counter drugs. consult your doctor immediately for quick and complete relief.

Sugary drinks elevate blood pressure Radha Chitale Soft drinks, juices and other sugar-sweetened beverages were linked to high blood pressure in adults, according to a study, and may be a possible intervention method for those at risk of the condition. Previous studies have shown that reduced sugary drink consumption is linked to reduced blood pressure. [Circulation 2010;121:2398-2406] High blood pressure is a risk factor for cardiovascular disease. In a cohort of 2,696 patients from the International Study of Macro/Micronutrients and Blood Pressure (INTERMAP) group, the researchers determined that there was a direct relationship between sugary drink intake and systolic and diastolic blood pressure, even after adjusting for body mass. [Hypertension 2011 Apr;57(4):695-701] Every extra sugary drink was associated with a 1 mmHg increase in systolic blood pressure (P<0.001) and a 0.8 mmHg increase in diastolic blood pressure. INTERMAP participants included adults aged 40-59 years fr

FDA Approves Once-Daily Rilpivirine for HIV Infection Emily Paulsen  The US Food and Drug Administration (FDA) announced today the approval of once-daily rilpivirine ( Edurant , Tibotec Therapeutics, a division of Centocor Ortho Biotech Inc) for treatment of HIV infection. Rilpivirine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) that may be taken once daily in combination with other antiretroviral drugs for HIV-infected, treatment-naive patients. "Patients may respond differently to various HIV drugs or experience varied side effects. FDA's approval of Edurant provides an additional treatment option for patients who are starting HIV therapy," said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research. The new drug gives clinicians an alternative to efavirenz, which has been considered the "gold standard" NNRTI — no other NNRTI has matched its efficacy since its approval in

Zoster and Pneumococcal Vaccines May Be Given Concomitantly News Author: Laurie Barclay, MD CME Author: Charles P. Vega, MD Giving pneumococcal and herpes zoster vaccines to patients during the same visit may be beneficial without compromising the protective effect of the zoster vaccine, according to the results of an observational study reported in the May 9 issue of Vaccine . These findings challenge information in a 2009 revision to the zoster vaccine package insert stating that the zoster vaccine and the pneumococcal vaccine should not be given concurrently because concomitant use resulted in reduced immunogenicity of the zoster vaccine. "Our study found no evidence that receiving the zoster vaccine and pneumococcal vaccine on the same day would compromise the immune response necessary to protect against herpes zoster, also known as shingles," said lead author Hung Fu Tseng, PhD, MPH, from the Kaiser Permanente Department of Research & Evaluation in Pasadena, Cali

Hi, friends do you know our national animal "ROYAL BENGAL TIGER'S"  population is decreasing day by day so Check out Save Our Tigers | Join the Roar photo courtesy: http://www.bingimagesearch.com/                                                            

Colesevelam Effective as Add-On Therapy in Type 2 Diabetes Colesevelam ( Welchol , Daiichi-Sankyo Pharmaceuticals) might not be a first choice for many clinicians in the treatment of type 2 diabetes; however, a post hoc analysis of 3 large randomized controlled trials reveals that it might be a good option as an add-on therapy for patients with both type 2 diabetes and high cholesterol. In the analysis of 696 patients receiving colesevelam, the medication reduced mean low-density-lipoprotein cholesterol by 16.5%, total cholesterol by 5.8%, and apolipoprotein B levels by 7.6% when used along with metformin background therapy and when compared with placebo ( P  < .0001), according to researchers here at the American Association of Clinical Endocrinology 20th Annual Meeting and Clinical Congress. Elevations in triglycerides — a known adverse effect of colesevelam, particularly when used in combination with sulfonylureas or insulin — were also modest in the treatment group, with a me

         FDA approves new treatment for Type 2 diabetes The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes. People with Type 2 diabetes do not produce or respond normally to insulin, a hormone that regulates the amount of glucose in the blood. Over time, high blood glucose levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage. "This approval provides another treatment option for the millions of Americans with Type 2 diabetes," said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “It is effective when used alone or when added to existing treatment regimens.” Type 2 diabetes is the most common form of the disease, affecting between 90 percent and 95 percent of the 24 million people in the Unite

                List  of  colleges  offering  Both   Pharm.D. and                                   Pharm.D. (Post Baccalaureate) To find out the list of  institutions that are offering pharm.D and pharm.D (post Baccalaureate) click on the link below http://www.pci.nic.in/CollegesCourses/Baccalaureate.aspx

                                                   WORLD RED CROSS DAY Pharmdfundsrmc team wishes the volunteers of red cross society on occasion of the "world red cross day".The efforts done by the volunteers of red cross society at the time of calamities are marvelous. They save the people in trouble with great care and they try to rescue with great effort The tradition of celebration of the World Red Cross Day on May 8th, was this year observed by paying tribute to the volunteers for their unprecedented contribution to the people in need. A seminar was held at the National Headquarter on the theme, ‘Our strength, Our future- Committed Volunteer’ and in this seminar the experienced members of Indian Red Cross Society, commended the volunteers for their selfless efforts. Since the inception of Red Cross, voluntary action has been its quintessence. Volunteering, serves as a means in helping the society to bridge the gap between the crisis and the crisis management. In the S

India's Drug Technical Advisory Board (DTAB) has decided to ban two controversial drugs — Gatifloxacine and Tegaserod — because of their side-effects. The decision was taken by DTAB's sub-committee headed by Dr Y K Gupta from AIIMS which met on Thursday. DTAB, however, could not make up its mind on the third controversial drug Deanxit and said, "More data is needed on the drug's side-effects." Confirming this to TOI, drug controller general of India Dr Surinder Singh said, "Gatifloxacine and Tegaserod will be withdrawn from the market in two weeks' time." Jointly, Gatifloxacine, Tegaserod and Deanxit do business of around Rs 70 crore annually in India. But for some time, there have been concerns on their safety. Gatifloxacine is used as an antibiotic. But according to Dr Singh, this drug is known to shoot up and also dip blood sugar levels. Drug expert Dr C M Gulati had told TOI that it is known to cause heart movement abnormality. Tegas

                          LIST OF DRUGS BANNED FOR MARKETING IN INDIA The Government of India vide notifications published in the Gazette of India vide G.S.R. No. 578 (E) dated 23/07/1983 and subsequent amendments, made under Section 26 A of Drugs and Cosmetics Act, 1940 has prohibited the manufacture, sale and distribution of the following categories of fixed dose combinations which do not have any therapeutic justification or are likely to involve risk to human beings: G.S.R. No. 578 (E) dt 23-07-1983 1. Amidopyrine. 2. Fixed dose combinations of vitamins with anti-inflammatory agents and tranquilizers. 3. Fixed dose combinations of Atropine and Analgesic and Antipyretics. 4. Fixed dose combinations of Strychnine and Caffeine in tonics. 5. Fixed dose combinations of Yohimbine and Strychnine with Testosterone and Vitamins. 6. Fixed dose combinations of Iron with Strychnine, Arsenic and Yohimbine. 7. Fixed dose combinations of Sodium Bromide/chloral hydrate with other dru

Ref. No. 14-185/2011-PCI/1167-3018 All Institutions approved by PCI for –                     19 APR 2011                    -     u/s 12 of the Pharmacy Act. -     conduct of course. Sub:    Book “Drug Information about commonly used drugs” for  Library of Pharmacy Institutions. Sir/Madam This has a reference to the subject cited above. In this connection, I am directed to state that the book “Drug information about commonly used drugs” by Sri P.P. Sharma and Dr. Ramendra Singh is quiet useful for the pharmacy students, hence pharmacy institutions may keep this book in their library. For further details, institutions may approach the authors in the matter. courtesy: http://www.pci.nic.in/